10-K: Harrow, Inc. Details Securities and Debt in 10-K Filing

Harrow, Inc.'s 10-K filing outlines the company's registered securities, including common stock and senior notes, along with details on capital structure, anti-takeover provisions, and debt obligations.

Summary

• Harrow, Inc. has two classes of securities registered under the Securities Exchange Act of 1934: common stock and senior notes due in 2026 and 2027.
• The company's authorized capital stock consists of 50,000,000 shares of common stock and 5,000,000 shares of preferred stock, both with a par value of $0.001 per share.
• As of March 18, 2024, there were 35,362,642 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.
• There are outstanding options to acquire 2,711,317 shares of common stock with a weighted average exercise price of $6.25 per share, 1,930,942 unvested restricted and performance-based stock units, and 215,539 restricted stock units awarded to directors.
• The company's 8.625% Senior Notes due 2026 have an aggregate principal amount of $75.0 million and mature on April 30, 2026.
• The 11.875% Senior Notes due 2027 have an aggregate principal amount of $40.25 million and mature on December 31, 2027.
• The notes are general unsecured, senior obligations and rank senior to common stock, pari passu with other unsecured debt, and subordinated to secured debt and subsidiary debt.
• The indenture does not limit the amount of indebtedness that the company or its subsidiaries may issue and does not contain any financial covenants.
• The company is subject to anti-takeover provisions under Delaware law, which may delay or prevent a change in control.
• The company has director and officer indemnification agreements that provide for indemnification to the fullest extent permitted by Delaware law.

Sentiment

Score: 6

Explanation: The document is factual and descriptive, providing details about the company's securities and debt. There is no strong positive or negative sentiment, but the lack of financial covenants in the debt agreement and the anti-takeover provisions could be seen as slightly negative.

Positives

• The company has a clear capital structure with defined amounts of authorized and outstanding shares.
• The company has access to capital through both equity and debt instruments.
• The company has director and officer indemnification agreements in place.

Negatives

• The senior notes are unsecured and subordinated to secured debt, which increases risk for noteholders.
• The indenture for the senior notes does not contain financial covenants, which provides less protection for noteholders.
• The company is subject to anti-takeover provisions, which may limit shareholder influence.

Risks

• The senior notes are unsecured and effectively subordinated to any secured indebtedness.
• The indenture for the senior notes does not contain financial covenants or restrictions on dividends or issuing/repurchasing securities.
• The company is subject to anti-takeover provisions under Delaware law, which may delay or prevent a change in control.
• The company's ability to pay interest and debt service payments associated with the notes is dependent on future performance and access to capital.

Future Outlook

The document does not contain specific forward-looking statements about future financial performance, but it does outline the terms and conditions of the company's securities and debt obligations.

Industry Context

This document provides a detailed look at Harrow's capital structure and debt obligations, which is typical for a public company's 10-K filing. The information is relevant for investors and stakeholders to understand the company's financial position and risk profile.

Comparison to Industry Standards

• The capital structure of Harrow, with both common stock and senior notes, is typical for a publicly traded company in the pharmaceutical industry.
• The use of senior notes as a financing tool is common among companies seeking to raise capital without diluting equity.
• The anti-takeover provisions are standard for Delaware corporations and are designed to protect the company from hostile takeovers.
• The indemnification agreements for directors and officers are also standard practice to attract and retain qualified individuals.
• Compared to other pharmaceutical companies, Harrow's debt levels and capital structure are within the typical range for a company of its size and stage of development. For example, companies like Bausch Health Companies Inc. (BHC) and Teva Pharmaceutical Industries Ltd. (TEVA) also utilize a mix of debt and equity financing, but their specific terms and conditions may vary based on their individual circumstances and credit ratings.
• The lack of financial covenants in the senior notes indenture is less common and may indicate a higher risk profile for the debt, as it provides less protection for noteholders compared to companies with more restrictive covenants, such as those found in the debt agreements of companies like Amgen Inc. (AMGN) or AbbVie Inc. (ABBV).
• The specific interest rates and maturity dates of Harrow's senior notes are comparable to other companies in the pharmaceutical sector with similar credit ratings and risk profiles. However, the absence of a sinking fund in Harrow's notes is less common and may increase the risk for noteholders, as it does not provide for a gradual reduction of the principal amount over time, unlike some other companies' debt instruments.

Stakeholder Impact

• Shareholders: The document provides information about the company's capital structure and potential risks, which is important for making investment decisions.
• Noteholders: The document outlines the terms and conditions of the senior notes, including the lack of financial covenants, which is important for assessing risk.
• Management: The document outlines the indemnification agreements, which provide protection for directors and officers.
• Potential Investors: The document provides a detailed overview of the company's securities and debt obligations, which is important for evaluating investment opportunities.

Key Dates

Keywords

common stock, senior notes, capital stock, indenture, anti-takeover, indemnification, securities, Delaware law, debt, NASDAQ